Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer.

Turner J, Chaudhary U.

Anticancer Drugs. 2009 Mar;20(3):215-6. doi: 10.1097/CAD.0b013e3283163c26.

PMID:
19104437
2.

Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.

Soga N, Arima K, Sugimura Y.

Jpn J Clin Oncol. 2008 Sep;38(9):617-22. doi: 10.1093/jjco/hyn071. Epub 2008 Aug 12.

PMID:
18697759
3.

Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.

Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME.

BJU Int. 2012 Dec;110(11):1729-35. doi: 10.1111/j.1464-410X.2012.11456.x. Epub 2012 Aug 29.

4.
5.

Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.

Nemoto K, Tomita Y.

Scand J Urol Nephrol. 2007;41(6):558-60.

PMID:
17853028
6.

Multimodality imaging in biochemical recurrence of prostate cancer: utility of (18)F-NaF PET/CT in early detection of metastasis.

Desai B, Gross ME, Jadvar H.

Rev Esp Med Nucl Imagen Mol. 2012 Jul-Aug;31(4):231-2. doi: 10.1016/j.remn.2012.03.008. Epub 2012 May 14. No abstract available.

7.
8.

Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal.

Kundranda MN, Muslimani A, Daw HA, Spiro TP.

Clin Genitourin Cancer. 2007 Sep;5(6):401-2.

PMID:
17956714
9.

Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.

Moul JW.

Cancer. 2009 Aug 1;115(15):3376-8. doi: 10.1002/cncr.24393. No abstract available.

10.

[Results of 125-iodine seed implant with preplanning system in 250 patients with prostate cancer].

Guinot JL, Ricós JV, Gimeno J, Tortajada MI, Carrascosa M, Santos M, Casanova J, Soler P, Crispín V, Arribas L.

Actas Urol Esp. 2011 Jun;35(6):339-44. doi: 10.1016/j.acuro.2011.02.003. Epub 2011 Apr 8. Spanish.

PMID:
21481974
11.

Biochemical remission after resection of prostate cancer lung metastasis.

Chao DH, Higgins JP, Brooks JD.

Urology. 2004 Mar;63(3):584-5.

PMID:
15028469
12.

Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.

Lloyd A, Penson D, Dewilde S, Kleinman L.

Prostate Cancer Prostatic Dis. 2008;11(2):153-9. Epub 2007 Jul 17.

PMID:
17637761
14.

Acute renal failure in a patient receiving treatment with suramin.

Smith A, Harbour D, Liebmann J.

Am J Clin Oncol. 1997 Aug;20(4):433-4.

PMID:
9256906
16.

Lack of energy, petechiae, elevated PSA level--Dx?

Subramaniam S, Choufani E, Manov A.

J Fam Pract. 2014 Oct;63(10):565-7. No abstract available.

PMID:
25343154
17.

Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.

Njiaju UO, Truica CI.

Clin Breast Cancer. 2010 Feb;10(1):E3-5. doi: 10.3816/CBC.2010.n.013.

PMID:
20133250
18.

Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.

Takeshita H, Kawakami S, Fukui I.

Int J Urol. 2009 Mar;16(3):337-8. doi: 10.1111/j.1442-2042.2008.02189.x. No abstract available.

19.

[Solitary peritoneal carcinomatosis in prostate cancer].

Brehmer B, Makris A, Wellmann A, Jakse G.

Aktuelle Urol. 2007 Sep;38(5):408-9. German.

PMID:
17907070

Supplemental Content

Support Center